This Project has been agreed as part of the Accelerated Access Collaborative (AAC).
The AAC was formed in response to the independently chaired Accelerated Access Review published in October
2016. The AAC brings industry, government and the NHS together to remove barriers to uptake of innovations, so
that NHS patients have faster access to certain products that can transform care.
The AAC supports the rapid uptake of products from 7 high-potential technology areas, selected by leaders in
the health and care system, with full evidence-based recommendations from NICE.
PCSK9 inhibitors for the management of hypercholesterolemia were selected as one of the seven NICE recommended
rapid uptake products to increase patient access and remove barriers across the health innovation landscape
Funding announced by government in July 2017 is available through the new Accelerated Access Collaborative
Pathway Transformation Fund (PTF) to help NHS organisations integrate the rapid uptake products into everyday
practices. Delivered with the support of the Academic Health Science Networks (AHSNs) the PTF seeks to improve
equality of access to these products.
The PTF, in relation to PCSK9 inhibitors, combines funding from NHS England, Amgen and Sanofi for selected
projects to meet the AAC objectives and increase PCSK9i uptake by addressing barriers such as:
- Lack of patient identification
- Inconsistent pathways
- Limited awareness
- Restricted prescribing
- Sporadic LDL-C measurement
- Treatment complexity
19 applications relating to PCSK9 inhibitors from 12 AHSNs were submitted to the AAC for funding from NHS England, Amgen and Sanofi and 6 were selected, including NHS Buckinghamshire CCG.
NHS England have provided equal PTF to the Academic Health and Science Network- North East North Cumbria (AHSN-NENC). AHSN-NENC will distribute this accordingly as agreed by the AAC to the 6 successful sites, one of which being the Partner for this project.
Buckinghamshire CCG and Amgen are working in partnership under a joint working agreement to transform lipid management pathways in primary care by
- Creation of Pharmacist-Led Lipid Management Service
- Development of a clear lipid management pathway for primary care
- Establishing a “Virtual” Consultant-Led Lipid Clinic
- Improved Coding
After baselining the current quality of data and coding, a strategy to enhance the frequency and accuracy of coding will be put in place. Outcomes data will be captured and used to refine and optimise the service. This will be critical to support the case for sustainability beyond the pilot.